CRMD - CorMedix, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
1.6900
-0.0900 (-5.06%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.7800
Open1.7400
Bid0.00 x 3100
Ask0.00 x 900
Day's Range1.5000 - 1.7700
52 Week Range0.1700 - 2.7400
Volume8,347,990
Avg. Volume2,995,191
Market Cap177.974M
Beta (3Y Monthly)3.53
PE Ratio (TTM)N/A
EPS (TTM)-0.49
Earnings DateMar 18, 2019 - Mar 22, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.75
Trade prices are not sourced from all markets
  • Here's Why CorMedix Dropped as Much as 27.1% Today
    Motley Fool2 days ago

    Here's Why CorMedix Dropped as Much as 27.1% Today

    The company announced an update after meeting the FDA.

  • ACCESSWIRE2 days ago

    CorMedix Inc. Announces FDA Meeting Update

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / February 14, 2019 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has begun discussions with the U.S. FDA regarding its recently completed and unblinded Phase 3 LOCK-IT-100 study to support regulatory approval for Neutrolin®, the Company's investigational product under development as a catheter lock solution for patients suffering from end stage renal disease undergoing hemodialysis. At the meeting, the FDA agreed that the Company could request consideration of Neutrolin for approval under the LPAD (Limited Population Pathway for Antibacterial and Antifungal Drugs) pathway. Data originally submitted to the FDA included preliminary analyses from 653 subjects at the time of the interim analysis, including the first 28 cases of catheter-related blood stream infection (CRBSI).

  • ACCESSWIRE3 days ago

    Biotech and Cannabis Stocks That Are Emerging

    HENDERSON, NV / ACCESSWIRE / February 13, 2019 / One you should research right away, BioRestorative Therapies, Inc. (BRTX) , a life sciences company focused on stem cell-based therapies, is developing ...

  • ACCESSWIRE3 days ago

    These Healthcare Stocks Could Surpass Investor Expectations

    Companies working in the healthcare sector are tasked with meeting the growing demand for effective treatment options given that, almost every day, medical experts discover a new disease or ailment. Premier Health Group (OTC:PHGRF) (CSE:PHGI), CAS Medical Systems Inc (CASM), CorMedix Inc (NYSE American: CRMD), and Viking Therapeutics Inc (VKTX) represent four healthcare companies determined to create products to help consumers have a better life.

  • ACCESSWIRE17 days ago

    Cormedix Inc. Announces Topline Analysis of the Full Data Set of Phase 3 Lock-It-100 Study Reinforces the Interim Results

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / January 30, 2019 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced the topline results of the full data set of the Company's Phase 3 LOCK-IT-100 study for Neutrolin® as a catheter lock solution in hemodialysis patients. The Company recently announced the topline results from the interim analysis of the study, which was terminated in August 2018 following the recommendation of the independent Data Safety Monitoring Board (DSMB), because efficacy had been demonstrated and the pre-specified level of statistical significance had been achieved. Efficacy data were available from 653 subjects at the time of the interim analysis, including the first 28 cases of catheter-related blood stream infection (CRBSI).

  • GlobeNewswire18 days ago

    Factors of Influence in 2019, Key Indicators and Opportunity within The Hain Celestial Group, Allegheny Technologies, NVR, Greif, CorMedix, and Enzo Biochem — New Research Emphasizes Economic Growth

    NEW YORK, Jan. 29, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Options Traders Expect Huge Moves in CorMedix (CRMD) Stock
    Zacks26 days ago

    Options Traders Expect Huge Moves in CorMedix (CRMD) Stock

    Investors need to pay close attention to CorMedix (CRMD) stock based on the movements in the options market lately.

  • ACCESSWIRElast month

    These 4 Healthcare Stocks Are Raising Expectations

    With the rise of global population, coupled with depletion of most common resources, consumer access to healthcare is crucial to securing the health and wellness of all living people, resulting in a need for companies in the space to meet these demands. As healthcare companies work to develop new methods for bettering the care provided to their patients, the industry, in its entirety, will unite to meet the demands and needs of consumers in the space looking for qualitative healthcare. Premier Health Group (OTC:PHGRF) (CSE:PHGI), LM Funding America Inc., (LMFA), CorMedix Inc (CRMD), and ContraFect Corp (CFRX) are 4 healthcare stocks representing companies invested in creating the best quality treatments for their patients.

  • ACCESSWIRElast month

    Cormedix Inc. Announces Highly Statistically Significant Topline Results For Neutrolin(R) From The Interim Analysis Of The Phase 3 Lock-It-100 Study

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / January 17, 2019 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced the topline results of the interim analysis of the Company's Phase 3 LOCK-IT-100 study for Neutrolin® as a catheter lock solution in hemodialysis patients. As previously announced, the study was terminated at the recommendation of the independent Data Safety Monitoring Board (DSMB) after the interim analysis was completed in July 2018, because efficacy had been demonstrated and the pre-specified level of statistical significance had been achieved.

  • ACCESSWIRElast month

    CorMedix Inc. Announces Resignation of Member of Its Board of Directors

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / January 16, 2019 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that Gary A. Gelbfish, MD FACS has resigned his position as a member of the Board of Directors, effective January 14, 2019.Dr. Gelbfish's most recent tenure on the board began in August 2017.He previously served on CorMedix's Board from December 2009 to June 2014, including a term as Board Chairman from 2012 to June 2014. Khoso Baluch, CorMedix Chief Executive Officer and a member of the Board stated, "We thank Gary for his service and guidance during the LOCK-IT-100 study.He provided significant insight that contributed to its successful completion.

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: Incyte and CorMedix

    NEW YORK, NY / ACCESSWIRE / January 16, 2019 /U.S. markets rose on Tuesday as Netflix helped push the tech sector higher after announcing it would raise the price of its monthly membership. Tech giants ...

  • ACCESSWIRElast month

    This Stock Generated 25X Returns In Just Five Years: Could BTCY Be At The Same Crossroads?

    The move to get patients out of doctors offices and hospitals quickly using virtual care and remote monitoring is underway. Technology is enabling the switch, and few subsectors have benefitted more than remote cardiac care. Companies like Biotelemetry (BEAT) have grown by leaps and bounds in the last few years as their proprietary remote cardiac monitoring devices have gained traction.

  • ACCESSWIRElast month

    Cormedix Announces Closing of $7.5 Million Senior Secured Convertible Debt Financing

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / January 3, 2019 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has closed and drawn a previously announced $7.5 million, senior secured convertible debt financing with its largest shareholder. At the investor's option, the loan is convertible into the Company's common stock at a price equal to $1.50 per share. Additionally, the loan will automatically convert at the conversion rate into shares of common stock, if, prior to the maturity date, the average closing sale price of the Company's common stock for any 20 trading days during any consecutive 30 trading days equals or exceeds 150% of the conversion price.

  • Implied Volatility Surging for CorMedix (CRMD) Stock Options
    Zacks2 months ago

    Implied Volatility Surging for CorMedix (CRMD) Stock Options

    Investors need to pay close attention to CorMedix (CRMD) stock based on the movements in the options market lately.

  • ACCESSWIRE2 months ago

    CBD and Biotech Plays on The Rise

    HENDERSON, NV / ACCESSWIRE / December 11, 2018 / We have found several companies releasing recent news we believe should be on your radar. Today we are highlighting: Delcath Systems, Inc. (DCTH), KushCo ...

  • ACCESSWIRE2 months ago

    Cormedix Receives Approval to Sell $5.4 Million of NOL Tax Benefits Through the New Jersey Economic Development Authority Program

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / December 10, 2018 / CorMedix Inc. (CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced the New Jersey Economic Development Authority (NJEDA) has approved the Company's application to participate in the New Jersey Technology Business Tax Certificate Transfer (NOL) program for State Fiscal Year 2018. The approval will allow CorMedix to transfer approximately $5.4 million of the total $6.1 million in available tax benefits to an unrelated, profitable New Jersey corporation in return for approximately $5.0 million in cash, which is anticipated by the end of 2018. Closing is subject to NJEDA's typical closing conditions, which are in process.

  • ACCESSWIRE3 months ago

    Biomedical Trends Fuel New Momentum For Healthcare Stocks; Premier Health Group, Inc. (OTC: PHGRF) (CSE: PHGI), Alliqua BioMedical, BioScrip, Coremedix

    CORAL GABLES, FL / ACCESSWIRE / November 28, 2018 / Healthcare stocks and biotechnology stocks have rallied during recent quarters. New developments in technology and drug therapies have boosted excitement within the market. Premier Health Group, Inc. (PHGRF) (PHGI) has engaged discussions with Licensed Producers under the Access to Cannabis for Medical Purposes Regulation, other licensed medical cannabis companies and government officials in order to establish a framework for both patient and physician education.

  • GlobeNewswire3 months ago

    Consolidated Research: 2018 Summary Expectations for Kadmon, Overstock, AECOM, Steelcase, CorMedix, and Corindus Vascular Robotics — Fundamental Analysis, Key Performance Indications

    NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • ACCESSWIRE3 months ago

    CBD and Biotech Stocks to Watch

    HENDERSON, NV / ACCESSWIRE / November 27, 2018 / CBD and biotech companies are on our radar this week. We are highlighting: Endonovo Therapeutics, Inc. (ENDV), Auris Medical Holding AG (EARS), CorMedix, ...

  • Associated Press3 months ago

    CorMedix: 3Q Earnings Snapshot

    On a per-share basis, the Berkeley Heights, New Jersey-based company said it had a loss of 11 cents. The pharmaceutical and medical device company posted revenue of $372,500 in the period. Its adjusted ...

  • ACCESSWIRE3 months ago

    CorMedix Inc. Reports Third Quarter Financial Results and Provides Business Update

    Conference Call today at 4:30 p.m. Eastern Time BERKELEY HEIGHTS, NJ / ACCESSWIRE / November 14, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing ...

  • ACCESSWIRE3 months ago

    CorMedix Inc. to Report Third Quarter 2018 Financial Results on Wednesday, November 14

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / November 6, 2018 / CorMedix Inc. (NYSE: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment ...

  • ACCESSWIRE3 months ago

    3 Healthcare Stocks Using Technology To Boost Growth

    CORAL GABLES, FL / ACCESSWIRE / November 2, 2018 / Health technology is defined by the World Health Organization as the "application of organized knowledge and skills in the form of devices, medicines, vaccines, procedures, and systems developed to solve a health problem and improve quality of lives." Healthcare companies are taking a new and novel approach the health tech in the form of new innovation that takes the guesswork out of tracking health & reporting results. Premier Health Group, Inc. (PHGRF)(PHGI.CN) saw its shares trade higher on Thursday. Market activity in the United States appears to have picked up after the company's most recent announcement.

  • Investopedia4 months ago

    Penny Stocks to Buy Using Technical Analysis for November 2018

    Penny stocks got battered and bruised during the month of October, undermined by a broad-based retreat that dropped the Russell 2000 small-cap index to an eight-month low. The broad market could post new lows in early November, but a profitable relief rally should unfold in coming weeks, favoring dip trades on penny stocks that have held technical support levels through the maelstrom. This month's penny stock list includes several of these plays, but it's important to think and act defensively, placing stop losses immediately after entry. Penny Stock Picks to Buy Using Technical Analysis for November 1.